NeuroMetrix, Inc. announced a collaboration with GlaxoSmithKline. The key elements of the collaboration are as follows: GSK Consumer Healthcare acquires exclusive ownership of Quell technology for markets outside the U.S. NeuroMetrix retains exclusive ownership of Quell technology in the U.S. market. GSK Consumer Healthcare and NeuroMetrix to co-fund development of Quell technology for a three-year period beginning in 2018 through 2020, with subsequent annual renewals by mutual agreement. GSK Consumer Healthcare to pay NeuroMetrix $5 million for the assets relating to Quell technology for markets outside the U.S and up to $21.5 million, upon the achievement of certain development and commercialization milestones.